PYC - PYC Therapeutics

[sharesontoast]

Here is today's release from ProactiveInvestors titled:

'Phylogica has big six months ahead'

http://www.proactiveinvestors.com.a...phylogica-has-big-six-months-ahead-64933.html

SoT
DYOR

 

[sharesontoast]

Here is the link to todays release:

Phylogica’s intracellular targeting drug achieves significant
reduction in tumours in animal model of cancer

http://www.aspectfinancial.com.au/d...zaWduYWwvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==

 

[sharesontoast]

Here is today's ANN

Phylogica exceeds gold-standard for treatment of MYC-driven cancer

More than 7 in 10 cancer cases depend on the mutant gene MYC for survival1. While recognised as an important cancer target, there are currently no effective MYC therapies available. This is due primarily to the inability to deliver an effective MYC inhibitor into the intracellular environment where MYC exists.

Phylogica recently announced the results of an independently performed
animal model of disease that demonstrated the ability of its Cell Penetrating Phylomers (CPPs) to deliver a drug cargo called OmoMYC inside cells to effectively inhibit MYC. Phylogica is now pleased to announce that:
• It has identified multiple Phylomer peptide cargoes that are able to
inhibit activity of MYC when delivered as drugs inside cancer cells;
• two of these Phylomer cargoes demonstrate superior activity to the gold
standard MYC inhibitor (OmoMYC) for the ability to kill cancer cells;
• it will evaluate an expanded set of potential candidates before selecting a lead cargo to assess for drug like properties when conjugated to its lead CPP and delivered in an animal model of cancer.

Perth, Australia, 16 November 2015: Phylogica Limited (ASXYC) has
successfully identified multiple proprietary Phylomer candidates with confirmed ability to bind and block intracellular MYC activity. Notably, two of these Phylogica candidates exhibit better killing activity in cancer cells than the previous gold standard OmoMYC when fused to Phylogica’s proprietary cell penetrating Phylomers.

Richard Hopkins, Phylogica’s CEO said “We’re delighted to have identified at least two proprietary Phylomers that represent the most potent inhibitors of MYC yet described. This outcome is a testament to the power of the Phylomer platform which has unique potential to discover and deliver our own drugs against some of the highest value (but currently undruggable) targets in cancer.”

In an additional encouraging finding, preliminary testing using one of the two Phylomers with superior activity to OmoMYC showed that this peptide was stable when incubated in serum for over 24 hours. Serum stability is an important ‘drug-like’property required to achieve activity in animal models of disease.

Phylogica’s CSO, Dr Paul Watt, commented “To date we’ve assayed less than 20% of the hits identified in the primary screens against MYC as fusions to our cell penetrating Phylomers. We are encouraged by the high hit rate so far and are confident that a larger pool of specific MYC inhibitors will emerge once the functional screens are completed early next year. Once we have identified a broader set of MYC inhibitors we will then choose the highest quality candidates for analysis in animal models of cancer.”

Phylogica’s differentiation in the field of intracellular drug delivery now extends from best in class cell penetrating Phylomers for drug delivery to best in class active biologics drug compounds active against MYC. The company is looking forward to publishing the results of animal models demonstrating the effects of systemically delivered proprietary CPP-cargo compounds in 2016.

http://www.aspectfinancial.com.au/d...zaWduYWwvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==

 

[System]

On November 28th, 2019, Phylogica Limited changed its name to PYC Therapeutics Limited.

 

[Knobby22]

I note the company has an entirely different drug and completed a raising.
Possibly worth keeping an eye on.

From the Chairman's speech.

PYC has taken a major step further in this transformation. In a co-venture with the Lions

Eye Institute of Western Australia, the Company conducted tests on a drug developed to treat Retinitis Pigmentosa - the leading cause of blindness in children. Results were so successful that it was decided to advance the program and seek Food and Drug Administration approval to test the drug in humans. This work has already commenced.

 

[myrtie100]

My pick for June's tipping competition.
On Monday PYC broken out on high volume. The following bars have all been inside bars of each other and the volume low and decreasing. It's formed a pennant type pattern.
With any luck, it might break out of this pattern to the upside.

 

[Skate]

My pick for June's tipping competition. On Monday PYC broken out on high volume. The following bars have all been inside bars of each other and the volume low and decreasing. It's formed a pennant type pattern. With any luck, it might break out of this pattern to the upside.

@myrtie100, your assumptions are very valid but it's not why I'm posting. There have been some comments that with the "Virus Crash" some stock has fallen off a traders radar giving me an opportunity to post two charts, one daily & the other weekly. The Ducati "DAILY" & "WEEKLY" Blue Bar Strategy charts display the relevant signals for (PYC). It's uncanny how accurate the signals are regardless of the periodicity.

(PYC) Daily Chart

(PYC) Weekly Chart

Skate.

 

[Malown1]

PYC - IMHO this one is worth putting on the watch list.

A) This 2020 final quarter will see 2 more validation test results released for curing childhood blindness - retina pigmentosa.
B) This 2020 final quarter will see up to 6 more proposed drug candidates for their proprietary platform.
C) Chairman is Alan Tribe whom bought IKEA to West & Sth Australia. Owns 30% of shares.

(Upfront: I do own shares.)
I believe this company still has legs at 12c they're trading at as of yesterday. (Friday 4/09/20)

 

[Malown1]

Another LTH of mine due for a breakout, and added to my tipping list for 2022.
Trading sideways mostly 2021, and with human trials starting circa Q1 for VP-001 and Central Nervous System target to be announced, this may be the kickstart required.

gltah.